Showing results (2851-2860 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|June 17, 2017
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United StatesMin Huang, Yanyan Lou, James Pellissier, et al.Pharmacoeconomics|January 21, 2010
Access with evidence development: the US experiencePenny E Mohr, Sean R TunisPharmacoeconomics|January 21, 2010
Access with evidence development in the UK: past experience, current initiatives and future potentialAndrew Briggs, Karen Ritchie, Elisabeth Fenwick, et al.Pharmacoeconomics|May 5, 2017
How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness AnalysisLaura Bojke, Andrea Manca, Miqdad Asaria, et al.Pharmacoeconomics|September 21, 2016
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission ModelChristiaan Dolk, Martin Eichner, Robert Welte, et al.Pharmacoeconomics|July 12, 2017
Performance-Based Risk-Sharing Arrangements: An Updated International ReviewJosh J Carlson, Shuxian Chen, Louis P GarrisonPharmacoeconomics|July 19, 2018
Medical Care Costs Associated with Genital Warts for Commercially Insured US PatientsKristina R Dahlstrom, Shuangshuang Fu, Wenyaw Chan, et al.Pharmacoeconomics|July 20, 2018
Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in JapanHaruhisa Fukuda, Takahisa Yano, Nobuyuki ShimonoPharmacoeconomics|July 14, 2018
The Future of Precision Medicine: Potential Impacts for Health Technology AssessmentJames Love-Koh, Alison Peel, Juan Carlos Rejon-Parrilla, et al.Pharmacoeconomics|June 28, 2018
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic CancerMahdi Gharaibeh, Ali McBride, David S Alberts, et al.Pageof 336